EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Repurposing SGLT2 and DPP‐4 inhibitors for mild cognitive impairment in type 2 diabetes mellitus: Insights from proteomics, target prediction and molecular docking

Shams T Osman, Perihan A Elzahhar, Md Abdul Hakim, Akeem Sanni, Noha A Hamdy, Waziha Tasnim Purba, Md Mostofa Al Amin Bhuiyan, Sherifdeen Onigbinde, Vishal Sandilya, Nayera W Hassan, Mahmoud Agami, Labiba K El-Khordagui und 6 weitere

British Journal of Pharmacology · 2026

DOI: 10.1111/bph.70331 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift British Journal of Pharmacology, 2026. Verfasst von Shams T Osman und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit nennt 84 Literaturangaben. Gefördert von: Welch Foundation, CH Foundation, AIU Research and Innovation Hub in Egypt.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose The rising prevalence of type 2 diabetes mellitus (T2D) has led to an increase in complications, including mild cognitive impairment. Accordingly, there is a growing interest in the potential neuroprotective benefits of newer anti‐diabetic drugs, such as dipeptidyl peptidase 4 inhibitors (DPP‐4is) and sodium–glucose cotransporter‐2 inhibitors (SGLT2is). Although clinical studies suggest that these drugs mitigate cognitive decline, the underlying mechanisms remain unclear. This study aimed to elucidate the potential mechanisms through which DPP‐4is or SGLT2is, in combination with metformin, confer neuroprotection. Experimental Approach We conducted a cross‐sectional study involving T2D patients on either metformin alone or in combination with a DPP‐4i or SGLT2i, alongside healthy controls. Cognitive and metabolic phenotypes were assessed, followed by serum proteomic profiling, computational drug target prediction, network analyses and molecular docking to identify signalling pathways linked to cognitive impairment. Key Results T2D patients on combination therapy demonstrated better cognitive function, independent of other phenotypic, metabolic and biochemical factors. Proteomic profiling revealed 36 differentially expressed proteins that were preserved or restored to control levels in the combination therapy group. Gene set enrichment analysis highlighted the modulation of the complement pathway, particularly the involvement of ficolin‐3 (FCN3). Molecular docking suggested that the sugar‐like or glycyl moieties in anti‐diabetic drug molecules interacted with FCN3, potentially inhibiting complement system activation. Such interaction was confirmed by binding studies using surface plasmon resonance. Conclusion and Implications These findings are significant in tailoring T2D treatment to reduce cognitive complications and exploring drug design to target neuroinflammatory disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cognitive DysfunctionDiabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsDrug RepositioningProteomicsMolecular Targeted TherapyMolecular Docking SimulationNeuroprotectionCase-Control StudiesMetforminDrug Therapy, CombinationCognitionCross-Sectional StudiesTreatment OutcomeProspective StudiesHumansMaleFemaleMiddle AgedAgedLectins

Stichwörter der Autor:innen

complement systemdipeptidyl peptidase 4 inhibitorsmild cognitive impairmentsodium–glucose cotransporter‐2 inhibitorstype 2 diabetes mellitus

Substanzen

Sodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsMetforminFCN3 protein, humanLectins

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
  • Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, Texas, USA.
  • The Research and Innovation Hub, Alamein International University, Alamein, Egypt.
  • Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
  • Department of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Bologna, Italy.

ORCID-Profile: Ahmed F El-Yazbi

Förderung

  • Welch Foundation
  • CH Foundation
  • AIU Research and Innovation Hub in Egypt

Zitieren

APA

Osman, S. T., Elzahhar, P. A., Hakim, M. A., Sanni, A., Hamdy, N. A., Purba, W. T., Bhuiyan, M. M. A. A., Onigbinde, S., Sandilya, V., Hassan, N. W., Agami, M., El-Khordagui, L. K., Spagnuolo, R., Naldi, M., Bartolini, M., Belal, A. S. F., Mechref, Y. S., & El-Yazbi, A. F. (2026). Repurposing SGLT2 and DPP‐4 inhibitors for mild cognitive impairment in type 2 diabetes mellitus: Insights from proteomics, target prediction and molecular docking. British Journal of Pharmacology. https://doi.org/10.1111/bph.70331

Vancouver

Osman ST, Elzahhar PA, Hakim MA, Sanni A, Hamdy NA, Purba WT, et al. Repurposing SGLT2 and DPP‐4 inhibitors for mild cognitive impairment in type 2 diabetes mellitus: Insights from proteomics, target prediction and molecular docking. British Journal of Pharmacology. 2026. doi:10.1111/bph.70331

BibTeX
@article{Osman2026,
  author = {Osman, Shams T and Elzahhar, Perihan A and Hakim, Md Abdul and Sanni, Akeem and Hamdy, Noha A and Purba, Waziha Tasnim and Bhuiyan, Md Mostofa Al Amin and Onigbinde, Sherifdeen and Sandilya, Vishal and Hassan, Nayera W and Agami, Mahmoud and El-Khordagui, Labiba K and Spagnuolo, Rosaria and Naldi, Marina and Bartolini, Manuela and Belal, Ahmed S F and Mechref, Yehia S and El-Yazbi, Ahmed F},
  title = {Repurposing SGLT2 and DPP‐4 inhibitors for mild cognitive impairment in type 2 diabetes mellitus: Insights from proteomics, target prediction and molecular docking},
  journal = {British Journal of Pharmacology},
  year = {2026},
  doi = {10.1111/bph.70331}
}
Kostenlos starten →